Catalyst Pharmaceuticals (NASDAQ:CPRX) Earns Outperform Rating from Analysts at Robert W. Baird

Stock analysts at Robert W. Baird assumed coverage on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) in a report released on Tuesday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $28.00 price target on the biopharmaceutical company’s stock. Robert W. Baird’s target price indicates a potential upside of 19.66% from the company’s previous close.

A number of other equities analysts also recently weighed in on the stock. Truist Financial boosted their target price on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, November 11th. HC Wainwright upped their price objective on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, January 10th. StockNews.com downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 11th. Stephens initiated coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They issued an “overweight” rating and a $35.00 price target on the stock. Finally, Bank of America reaffirmed a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Catalyst Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $32.25.

Catalyst Pharmaceuticals Stock Up 1.3 %

Shares of CPRX stock opened at $23.40 on Tuesday. The company has a market capitalization of $2.79 billion, a price-to-earnings ratio of 19.83, a P/E/G ratio of 2.25 and a beta of 0.80. The firm has a fifty day moving average of $22.05 and a 200-day moving average of $20.85. Catalyst Pharmaceuticals has a 12-month low of $13.12 and a 12-month high of $24.64.

Insider Activity

In related news, insider Gary Ingenito sold 12,000 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total transaction of $272,640.00. Following the sale, the insider now owns 51,391 shares of the company’s stock, valued at $1,167,603.52. This represents a 18.93 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Steve Miller sold 50,000 shares of Catalyst Pharmaceuticals stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the completion of the transaction, the insider now directly owns 686,996 shares of the company’s stock, valued at $15,065,822.28. This represents a 6.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 79,500 shares of company stock valued at $1,754,140. 11.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Large investors have recently bought and sold shares of the company. abrdn plc acquired a new position in shares of Catalyst Pharmaceuticals in the 4th quarter valued at approximately $10,115,000. Jane Street Group LLC raised its position in Catalyst Pharmaceuticals by 245.4% during the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock valued at $7,990,000 after purchasing an additional 285,564 shares in the last quarter. Walleye Capital LLC bought a new stake in Catalyst Pharmaceuticals during the third quarter worth $4,936,000. Allspring Global Investments Holdings LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 146.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 366,444 shares of the biopharmaceutical company’s stock valued at $7,285,000 after purchasing an additional 217,956 shares in the last quarter. Finally, Pacer Advisors Inc. increased its stake in shares of Catalyst Pharmaceuticals by 5.4% in the 4th quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company’s stock valued at $61,681,000 after purchasing an additional 151,495 shares during the last quarter. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.